EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N Chi iD, Dana Rathkopf, Matthew R Smith, Eleni Efstathiou iD, Gerhardt Attard iD, David Olmos iD, Ji Youl Lee iD, Eric J Small iD, Andrea J Pereira de Santana Gomes iD, Guilhem Roubaud, Marniza Saad, Bogdan Zurawski und 9 weitere

Journal of Clinical Oncology · 20.06.2023 · 41 (18) · 3339-3351

DOI: 10.1200/jco.22.01649 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2023. Verfasst von Kim N Chi und 20 weiteren Autor:innen. Beteiligte Einrichtung: BC Cancer - Vancouver Center, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Abiraterone Acetate, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 357-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition. METHODS MAGNITUDE (ClinicalTrials.gov identifier: NCT03748641 ) is a phase III, randomized, double-blinded study that evaluates niraparib and abiraterone acetate plus prednisone (niraparib + AAP) in patients with (HRR+, n = 423) or without (HRR−, n = 247) HRR-associated gene alterations, as prospectively determined by tissue/plasma-based assays. Patients were assigned 1:1 to receive niraparib + AAP or placebo + AAP. The primary end point, radiographic progression-free survival (rPFS) assessed by central review, was evaluated first in the BRCA1/2 subgroup and then in the full HRR+ cohort, with secondary end points analyzed for the full HRR+ cohort if rPFS was statistically significant. A futility analysis was preplanned in the HRR− cohort. RESULTS Median rPFS in the BRCA1/2 subgroup was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.6 v 10.9 months; hazard ratio [HR], 0.53; 95% CI, 0.36 to 0.79; P = .001). In the overall HRR+ cohort, rPFS was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.5 v 13.7 months; HR, 0.73; 95% CI, 0.56 to 0.96; P = .022). These findings were supported by improvement in the secondary end points of time to symptomatic progression and time to initiation of cytotoxic chemotherapy. In the HRR− cohort, futility was declared per the prespecified criteria. Treatment with niraparib + AAP was tolerable, with anemia and hypertension as the most reported grade ≥ 3 adverse events. CONCLUSION Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP. [Media: see text]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abiraterone AcetateProstatic Neoplasms, Castration-ResistantMaleHumansBRCA1 ProteinBRCA2 ProteinPrednisoneAntineoplastic Combined Chemotherapy ProtocolsIndazolesPiperidines

Substanzen

Abiraterone AcetateBRCA1 ProteinBRCA2 ProteinPrednisoneBRCA1 protein, humanniraparibIndazolesPiperidinesBRCA2 protein, human

Autor:innen und Institutionen

  • BC Cancer - Vancouver Center, University of British Columbia, Vancouver, BC, Canada.
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY.
  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA.
  • Houston Methodist Cancer Center, Houston, TX.
  • University College London, London, UK.
  • Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.

ORCID-Profile: Kim N Chi, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J Small, Andrea J Pereira de Santana Gomes, Gary E Mason, Shahneen Sandhu

Förderung

  • NCI NIH HHS

Zitieren

APA

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., Saad, M., Zurawski, B., Sakalo, V., Mason, G. E., Francis, P., Wang, G., Wu, D., Diorio, B., Lopez-Gitlitz, A., …, & MAGNITUDE Principal Investigators (2023). Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 41(18), 3339-3351. https://doi.org/10.1200/jco.22.01649

Vancouver

Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 2023;41(18):3339-3351. doi:10.1200/jco.22.01649

BibTeX
@article{Chi2023,
  author = {Chi, Kim N and Rathkopf, Dana and Smith, Matthew R and Efstathiou, Eleni and Attard, Gerhardt and Olmos, David and Lee, Ji Youl and Small, Eric J and Pereira de Santana Gomes, Andrea J and Roubaud, Guilhem and Saad, Marniza and Zurawski, Bogdan and Sakalo, Valerii and Mason, Gary E and Francis, Peter and Wang, George and Wu, Daphne and Diorio, Brooke and Lopez-Gitlitz, Angela and Sandhu, Shahneen and MAGNITUDE Principal Investigators, MAGNITUDE Principal Investigators},
  title = {Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {18},
  pages = {3339--3351},
  doi = {10.1200/jco.22.01649}
}
Kostenlos starten →